News
ZBH
120.05
-1.03%
-1.25
Zimmer Biomet Holdings (NYSE:ZBH investor three-year losses grow to 26% as the stock sheds US$1.5b this past week
Zimmer Biomet Holdings, Inc. Share price is down 30% in the last three years, falling short of the market return of 16%. The company has shed US$1.5b from its value in the past 7 days. The share price does not reflect the underlying business performance of the company. Zimmer Biomet has a modest 0.8% dividend yield. The company's share price has underperformed the market over the last year.
Simply Wall St · 1d ago
RBC Capital Sticks to Their Buy Rating for Zimmer Biomet Holdings (ZBH)
TipRanks · 1d ago
BUZZ-U.S. STOCKS ON THE MOVE-WiSA Technologies, Rivian Automotive, Cigna Group
The Nasdaq and the S&P 500 were muted on Tuesday as higher Treasury yields pressured equities. The blue-chip Dow bucked the trend on robust results from health insurance heavyweight UnitedHealth. The Dow Jones Industrial Average was up 0.13% at 37,783.35. UnitedHealth Group's quarterly results beat expectations.
Reuters · 2d ago
BUZZ-Medical device makers fall after J&J's medtech unit misses sales estimates
Shares of medical device makers fall between 1% and 3% after Johnson & Johnson's JNJ.N medical devices unit reports Q1 sales of $7.82 bln. Analysts point to weakness in JNJ's vision care products and surgical devices. Stryker, Zimmer Biomet and Medtronic among those down.
Reuters · 2d ago
UPDATE 5-J&J's medical device sales fall short, cancer drugs seen growing
J&J's medical device sales fall short, cancer drugs seen growing. Sales of psoriasis drug Stelara come in lower than expected. The company's large medical devices business reported $7.82 billion in sales for first quarter. J&J shares were down 1.3% in after-hours trading.
Reuters · 2d ago
BUZZ-Truist bets on a 'beat & raise' Q1 for some med-tech players
Brokerage Truist Securities expects Q1 results beat and forecast raises for medical device makers Boston Scientific Corp BSX.N and Intuitive Surgical. Truist believes medical-technology sector will see rising earnings this quarter. Medical device makers have been benefitting from a resurgence in demand for joint replacements.
Reuters · 3d ago
First Week of April 19th Options Trading For Zimmer Biomet Holdings (ZBH)
NASDAQ · 3d ago
Weekly Report: what happened at ZBH last week (0408-0412)?
Weekly Report · 3d ago
U.S. RESEARCH ROUNDUP- Blackstone, Coupang, Wells Fargo
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Blackstone, Coupang, Wells Fargo & Co and Union Pacific raise their targets. 4D Molecular Therapeutics and Astera Labs are among the companies with new coverage on Monday.
Reuters · 3d ago
U.S. Wide-Moat Stocks On Sale - The April 2024 Heat Map
As of April 11, there were 158 U.S. Wide-moat stocks meeting Morningstar's criteria. Only 4.4% of these stocks earned a 5-star valuation rating. The heat map of the most investable candidates lists the best companies on sale. We focus on the most attractively valued stocks with a wide- moat rating.
Seeking Alpha · 6d ago
Weekly Report: what happened at ZBH last week (0401-0405)?
Weekly Report · 04/08 09:15
Zimmer Biomet Holdings Price Target Raised to $130.00/Share From $125.00 by Evercore ISI Group
Dow Jones · 04/04 17:16
Zimmer Biomet Holdings Is Maintained at In-Line by Evercore ISI Group
Dow Jones · 04/04 17:16
Evercore ISI Group Maintains In-Line on Zimmer Biomet Holdings, Raises Price Target to $130
Benzinga · 04/04 17:06
Zimmer Biomet Reveals Partnerships With Three Pickleball Organizations In US
Benzinga · 04/04 11:34
Zimmer Biomet Becomes First and Only Official Medical Device Partner of Association of Pickleball Players, Professional Pickleball Association, and USA Pickleball
Zimmer Biomet is the first and only medical device partner for the sport of pickleball. Pickleball is one of America's fastest-growing sports. The sport has 48.3 million players and millions of spectators in the United States. Zimmer Biomet will educate and raise awareness of the importance of joint health.
PR Newswire · 04/04 11:30
Unveiling 7 Analyst Insights On Zimmer Biomet Holdings
Zimmer Biomet Holdings has an average price target of $134.29. The company's 12-month price target has risen by 5.57% from the previous average of $127.20. 7 analysts have shared their evaluations of Zimmer Biometric Holdings in the last three months. Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants.
Benzinga · 04/03 17:00
Zimmer Biomet Holdings Is Maintained at Neutral by Citigroup
Dow Jones · 04/03 16:14
Zimmer Biomet Holdings Price Target Raised to $140.00/Share From $134.00 by Citigroup
Dow Jones · 04/03 16:14
Citigroup Maintains Neutral on Zimmer Biomet Holdings, Raises Price Target to $140
Benzinga · 04/03 16:03
More
Webull provides a variety of real-time ZBH stock news. You can receive the latest news about Zimmer Biomet through multiple platforms. This information may help you make smarter investment decisions.
About ZBH
Zimmer Biomet Holdings, Inc. is a global medical technology company. Its segments include Americas, EMEA, and Asia Pacific. The Company designs, manufactures and markets orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; craniomaxillofacial and thoracic (CMFT) products; surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence. Its other product category primarily includes its robotic, surgical and bone cement products. Its products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Its knee brands include the Persona Knee, NexGen Knee Implants, Vanguard Knee, and Oxford Partial Knee. Its hip brands include the Taperloc Hip System, Avenir Complete Hip System, Arcos Modular Hip System, and G7 Acetabular System. Its S.E.T. product category includes sports medicine, biologics, foot and others.